Key terms
About RGNX
REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest RGNX news
May 10
1:43am ET
Buy Rating Affirmed for RegenXBio on Clinical Progress and Promising Therapeutic Candidates
May 10
1:29am ET
Buy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid Financials
May 09
6:54am ET
RBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)
May 09
3:26am ET
RegenXBio (RGNX) Receives a Buy from Barclays
May 08
4:19pm ET
Regenxbio reports Q1 EPS ($1.38), consensus ($1.26)
Mar 28
7:09am ET
Regenxbio’s ABBV-RGX-314 featured in published study for wet AMD
Mar 11
10:10pm ET
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (QDEL), OrthoPediatrics (KIDS) and RegenXBio (RGNX)
Mar 11
9:34am ET
Regenxbio initiated with a Buy at H.C. Wainwright
Mar 08
7:15am ET
RBC Capital upgrades Regenxbio to Outperform, sees positive risk-reward
Mar 08
5:18am ET
Regenxbio upgraded to Outperform from Sector Perform at RBC Capital
Mar 07
7:12am ET
Analysts Are Bullish on These Healthcare Stocks: RegenXBio (RGNX), Biomea Fusion (BMEA)
Mar 07
7:01am ET
Regenxbio price target raised to $55 from $45 at Barclays
Mar 07
6:08am ET
Regenxbio 4.57M share Spot Secondary priced at $23.00
Mar 06
4:11pm ET
Regenxbio announces $125M common stock offering
Mar 06
9:50am ET
Nvidia initiated, Target upgraded: Wall Street’s top analyst calls
Mar 06
8:09am ET
Leerink more bullish on Regenxbio, upgrades to Outperform
Mar 06
8:03am ET
Regenxbio upgraded to Outperform from Market Perform at Leerink
Mar 06
6:57am ET
Regenxbio price target raised to $39 from $34 at Baird
Mar 05
2:55pm ET
RegenXBio’s RGX-202 Hold Rating: Balancing Promising DMD Trial Outcomes with Competitive Market Challenges
Mar 05
7:12am ET
Regenxbio’s RGX-202 shows initial efficacy in Duchenne
Mar 01
1:16am ET
Optimistic Outlook for RegenXBio’s Gene Therapy Pipeline and Regulatory Prospects Spurs Buy Rating
Mar 01
1:01am ET
Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), uniQure (QURE) and RegenXBio (RGNX)
Feb 28
7:18am ET
RBC Capital Remains a Hold on RegenXBio (RGNX)
Feb 28
6:56am ET
RegenXBio: A Cautious Hold Amidst Gene Therapy Uncertainties and Pending Milestones
Feb 28
3:36am ET
RegenXBio (RGNX) was downgraded to a Buy Rating at Barclays
Feb 27
4:08pm ET
Regenxbio expects cash to fund operations into 2H25
Feb 27
4:06pm ET
Regenxbio reports Q4 EPS ($1.34), consensus ($1.27)
Feb 21
5:21am ET
Regenxbio resumed with an Outperform at Raymond James
Feb 12
6:45am ET
Maintaining Hold on RegenXBio: A Cautious Stance Amidst Pipeline Uncertainties and Market Competition
Feb 09
11:12am ET
Biotech Alert: Searches spiking for these stocks today
No recent press releases are available for RGNX
RGNX Financials
Key terms
Ad Feedback
RGNX Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
RGNX Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
